Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment

References

• Cancer Facts & Figures 2016Atlanta, GAAmerican Cancer Society2016 Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdfAccessed October 28, 2016
   Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• McArthurGAChapmanPBRobertCSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLancet Oncol201415332333224508103
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• RobertCKaraszewskaBSchachterJImproved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med20143721303925399551
   PubMed Web of Science ®Google Scholar
• LongGVStroyakovskiyDGogasHDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLancet2015386999244445126037941
   PubMed Web of Science ®Google Scholar
• LarkinJAsciertoPADrénoBCombined vemurafenib and cobimetinib in BRAF-mutated melanomaN Engl J Med2014371201867187625265494
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVKEYNOTE-006 investigatorsPembrolizumab versus Ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• BrownRButowPWilson-GendersonMBernhardJRibiKJuraskovaIMeeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomesJ Clin Oncol201230885786222312102
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• KellyCASCO cancer drug valuation tool will incorporate patient preferencesPinksheet Available from: https://pink.pharmamedtechbi.com/PS079469/ASCO-Cancer-Drug-Valuation-Tool-Will-Incorporate-Patient-Preferences. Published 2016Accessed April 11, 2016
   Google Scholar
• KilbridgeKLWeeksJCSoberAJPatient preferences for adjuvant interferon alfa-2b treatmentJ Clin Oncol200119381282311157035
   PubMed Web of Science ®Google Scholar
• KrammerRHeinzerlingLTherapy preferences in melanoma treatment – willingness to pay and preference of quality versus length of life of patients, physicians and healthy controlsPLoS One2014911e11123725369124
   PubMed Web of Science ®Google Scholar
• OkenMCreechRTormeyDToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496567165009
   PubMed Web of Science ®Google Scholar
• KuhfeldWMarketing Research Methods in SAS: Experimental Design, Choice, Conjoint, and Graphical Techniques Available from: https://support.sas.com/techsup/technote/mr2010.pdf. Published 2010Accessed April 20, 2017
   Google Scholar
• ShafeyMLupichukSMDoTOwenCStewartDAPreferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experimentBone Marrow Transplant201146796296920935681
   PubMed Web of Science ®Google Scholar
• KunnemanMPieterseAHStiggelboutAMTreatment preferences and involvement in treatment decision making of patients with endometrial cancer and cliniciansBr J Cancer2014111467467924921911
   PubMed Web of Science ®Google Scholar
• ArellanoJHauberABMohamedAFPhysicians’ preferences for bone metastases drug therapy in the United StatesValue Health2015181788325595237
   PubMed Web of Science ®Google Scholar
• NathanHBridgesJFSchulickRDUnderstanding surgical decision making in early hepatocellular carcinomaJ Clin Oncol201129661962521205759
   PubMed Web of Science ®Google Scholar
• daCosta DiBonaventuraMCopherRBasurtoEFariaCLorenzoRPatient preferences and treatment adherence among women diagnosed with metastatic breast cancerAm Heal Drug Benefits201477386396
   PubMedGoogle Scholar
• WongYNEglestonBLSachdevaKCancer patients’ trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative settingMed Care201351983884523872905
   PubMed Web of Science ®Google Scholar
• KorfageIJde KoningHJHabbemaJDFSchröderFHEssink-BotMLSide-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?BJU Int200799480180617233804
   PubMed Web of Science ®Google Scholar
• GlennBAChenKLChangLCLinTBastaniRSkin examination practices among melanoma survivors and their childrenJ Cancer Educ201732233534326856594
   PubMed Web of Science ®Google Scholar
• SmithTSteinKDMehtaCCThe rationale, design, and implementation of the American Cancer Society’s studies of cancer survivorsCancer2007109111217146781
   PubMed Web of Science ®Google Scholar
• MuscaritoliMRossi FanelliFMolfinoAPerspectives of health care professionals on cancer cachexia: results from three global surveysAnn Oncol201627122230223628007753
   PubMed Web of Science ®Google Scholar